On November 20, 2020 Thyas reported that it has signed an advisory agreement with Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy, Kyoto University Hospital ("KiCONNECT"; Sakyo-ku, Kyoto, Director Dr. Manabu Muto) for strategic planning for a clinical trial of autologous iPS cell-derived cytotoxic T cell therapy (Press release, Thyas , NOV 20, 2020, View Source [SID1234629211]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!